SIRT1 mRNA Expression May Be Associated with Energy Expenditure and Insulin Sensitivity

Running title: SIRT1 expression, energy expenditure and insulin sensitivity

Jarno Rutanen¹, Nagendra Yaluri¹, Shalem Modi¹, Jussi Pihlajamäki¹, Markku Vänttinen¹, Paula Itkonen¹, Sakari Kainulainen², Hiroyasu Yamamoto³⁴, Marie Lagouge³, David A. Sinclair⁵, Peter Elliott⁶, Christoph Westphal⁶, Johan Auwerx³⁴, and Markku Laakso¹

¹ Department of Medicine, University of Kuopio and Kuopio University Hospital, Kuopio, Finland
² Department of Clinical Radiology, University of Kuopio, Kuopio, Finland
³ Institut de Génétique et de Biologie Moléculaire et Cellulaire, CNRS/INSERM/ULP, Illkirch, France
⁴ Laboratory of Integrative and Systems Physiology, Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland
⁵ Department of Pathology and Glenn Labs for Aging research, Harvard Medical School, Boston, MA 02115, USA
⁶ Sirtris Pharmaceuticals, Cambridge, MA, USA

Correspondence:
Markku Laakso, MD,
E mail: markku.laakso@kuh.fi

Submitted 11 August 2009 and accepted 20 January 2010.

Additional information for this article can be found in an online appendix at http://diabetes.diabetesjournals.org

This is an uncopyedited electronic version of an article accepted for publication in Diabetes. The American Diabetes Association, publisher of Diabetes, is not responsible for any errors or omissions in this version of the manuscript or any version derived from it by third parties. The definitive publisher-authenticated version will be available in a future issue of Diabetes in print and online at http://diabetes.diabetesjournals.org.
Objective - Sirtuin 1 (SIRT1) is implicated in the regulation of mitochondrial function, energy metabolism, and insulin sensitivity in rodents. No studies are available in humans to demonstrate that SIRT1 expression in insulin sensitive tissues is associated with energy expenditure and insulin sensitivity.

Research Design And Methods - Energy expenditure (EE), insulin sensitivity, and SIRT1 mRNA adipose tissue expression (N=81) were measured by indirect calorimetry, euglycemic hyperinsulinemic clamp, and quantitative RT-PCR in 247 non-diabetic offspring of type 2 diabetic patients.

Results - High EE during the clamp ($r=0.375, P = 2.8\times10^{-9}$) and high ΔEE (EE during the clamp - EE in the fasting state) ($r=0.602, P = 2.5\times10^{-24}$) were associated with high insulin sensitivity. Adipose tissue SIRT1 mRNA expression was significantly associated with EE ($r = 0.289, P = 0.010$) and with insulin sensitivity ($r = 0.334, P = 0.002$) during hyperinsulinemic euglycemic clamp. Furthermore, SIRT1 mRNA expression correlated significantly with the expression of several genes regulating mitochondrial function and energy metabolism (e.g. PGC-1β, estrogen-related receptor α, nuclear respiratory factor -1, mitochondrial transcription factor A), and with several genes of the respiratory chain (e.g. including NADH dehydrogenase (ubiquinone) 1α subcomplex, 2, cytochrome c, cytochrome c oxidase subunit IV, and ATP synthase).

Conclusions - Impaired stimulation of EE by insulin and low SIRT1 expression in insulin sensitive tissues are likely to reflect impaired regulation of mitochondrial function associated with insulin resistance in humans.
Committed mitochondrial function in skeletal muscle predisposes to insulin resistance and type 2 diabetes (1,2). In contrast, physical activity and weight loss in obese and sedentary subjects stimulate mitochondrial biogenesis and improve insulin sensitivity (3). Animal and human studies have shown that mitochondrial function is associated with insulin sensitivity but the mechanisms explaining this association are largely unknown (4).

The mammalian sirtuins SIRT1-SIRT7 are implicated in gene silencing, mitochondrial function, energy homeostasis, insulin sensitivity and longevity (5). We previously demonstrated that the treatment with SIRT1 activator, resveratrol, enhanced mitochondrial activity and protected mice from diet-induced obesity and insulin resistance (4). The effects of resveratrol were seen in both muscle and adipose tissue and resulted in an increase in mitochondrial function, which translated into an increase in energy expenditure (EE) and insulin sensitivity. Small molecule activators of SIRT1, that are structurally unrelated to resveratrol, have also been shown to improve insulin sensitivity, lower plasma glucose, and increase mitochondrial capacity (6). In many rodent models (4, 7) the up-regulation of the oxidative phosphorylation (OXPHOS) pathway is coordinated by peroxisome proliferator-activated receptor gamma coactivator α (PGC-1α), which is a target of SIRT1 (8). Similarly, insulin resistance in human skeletal muscle has been associated with decreased mitochondrial oxidative capacity and ATP synthesis, and decreased expression of genes that control mitochondrial activity, including PGC-1α (9-11).

The offspring of type 2 diabetic subjects are known to be insulin resistant and they have defects in mitochondrial OXPHOS associated with increased intramyocellular lipid content (9). The association of EE and insulin sensitivity with SIRT1 and PGC-1α mRNA expression has not been previously investigated. Therefore, we studied here the association of EE, insulin sensitivity and adipose tissue SIRT1 and PGC-1α mRNA expression in 247 non-diabetic offspring of subjects with type 2 diabetes.

**RESEARCH DESIGN AND METHODS**

**Participants.** The subjects were selected from an ongoing study and included healthy non-diabetic offspring of patients with type 2 diabetes, as previously described (12). The diabetic patients (probands) were randomly selected among type 2 diabetic subjects living in the region of the Kuopio University Hospital. Spouses of the probands had to have a normal glucose tolerance in an oral glucose tolerance test (OGTT). The study protocol was approved by the Ethics Committee of the University of Kuopio. All study subjects gave an informed consent. A total of 247 offspring (1-3 from each family) were studied. Their mean (±SD) age was 35.1 ± 6.3 years, and body mass index (BMI) 26.3 ± 4.7 kg/m².

**Clinical and laboratory methods.** Height and weight were measured to the nearest 0.5 cm and 0.1 kg, respectively. BMI was calculated as weight (kg) divided by height (m) squared. On the first day an OGTT was performed with 75 g of glucose. Subjects with normal glucose tolerance (N = 210), isolated impaired fasting glucose (N = 6) or impaired glucose tolerance (N = 31), defined on the basis of the WHO criteria (13), were included in further studies. An intravenous glucose tolerance test (IVGTT) was performed to determine the first-phase insulin release after an overnight fast. After baseline blood collection, a bolus of glucose (300 mg/kg in a 50% solution) was given within 30 seconds into the antecubital vein. Samples for the measurement of blood glucose and plasma
SIRT1 expression, energy expenditure and insulin sensitivity

insulin (arterialized venous blood) were drawn at –5, 0, 2, 4, 6, 8, 10, 20, 30, 40, 50, and 60 minutes. After an IVGTT, the degree of insulin sensitivity was evaluated with the euglycemic hyperinsulinemic clamp technique (insulin infusion rate of 40 mU · min⁻¹ · m⁻² body surface area) as previously described (14). Blood glucose was clamped at 5.0 mmol/L for the next 120 minutes by infusion of 20% glucose at various rates according to blood glucose measurements performed at 5-minute intervals. The mean amount of glucose infused during the last 20 minutes of the clamp was used to calculate the rates of whole body glucose uptake (WBGU) and divided with lean body mass (LBM) for statistical analyses. Non-oxidative glucose metabolism (per LBM) was calculated as the difference between the rates of WBGU/LBM and glucose oxidation (per LBM). Indirect calorimetry was performed with a computerized flow-through canopy gas analyzer system (DELTATRAC, TM Datex) as previously described (14). The mean value of the data during the last 20 minutes of the clamp was used to calculate glucose and lipid oxidation. Protein, glucose, and lipid oxidation were calculated according to the method reported by Ferrannini (15). A CT scan (Siemens Volume Zoom) at the level of fourth lumbar vertebra was performed to evaluate the amount of intra-abdominal and subcutaneous fat as previously described (14). Blood and plasma glucose were measured by the glucose oxidase method (Glucose & Lactate Analyzer 2300 Stat Plus, Yellow Springs Instrument Co, Inc), and plasma insulin was determined by radioimmunoassay (Phadeseeph Insulin RIA 100, Pharmacia Diagnostics AB; 125J RIA Kit, Incstar Co, respectively). Serum free-fatty acids (FFAs) were measured by an enzymatic method from Wako Chemicals GmbH. Nonprotein urinary nitrogen was measured by automated Kjeldahl method as previously described (14). Plasma concentrations of tumor necrosis factor-α (TNF-α) and cytokines (interleukin [IL]-1 receptor antagonist [IL-1RA], IL-6, IL-8, IL-10, IL-18, interferon gamma [IFNγ]) and serum levels of soluble adhesion molecules (intercellular adhesion molecule [ICAM-1], vascular cell adhesion molecule [VCAM-1], E-selectin, and P-selectin) were measured with high-sensitivity assay kits from R&D Systems. IL-8 was measured with a kit from Biosource International. High-sensitivity C-reactive protein (hs-CRP) was measured with an Immulite analyzer and a DPC high-sensitivity CRP assay.

Gene expression studies in offspring of type 2 diabetic parents. Subcutaneous fat needle biopsies were taken after an overnight fast in a supine position at the level of the umbilicus during local anesthesia. Total RNA from adipose tissue (N=81) was isolated with RNeasy Lipid Tissue Mini kit (Qiagen GmbH) and treated with DNase (DNA-free, Ambion). Total RNA from skeletal muscle biopsies (N=11) was isolated with QIAzol (Qiagen GmbH) and cleaned with RNeasy Plus Micro Kit (Qiagen GmbH). RNA was transcribed to cDNA using random primers and a High Capacity cDNA Reverse Transcription Kit (Applied Biosystems). Quantitative RT-PCRs were performed in a 7 500 Real-Time PCR System (Applied Biosystems) using 6 ng (RNA equivalents) of cDNA as template, gene-specific primers and probes (Applied Biosystems; information on primers and probes available upon request). Expression levels of different genes were normalized to large ribosomal protein P0 (adipose tissue; Hs99999902_ml, Applied Biosystems) or to β-actin (skeletal muscle; Hs99999903_ml, Applied Biosystems) using the standard curve method.

Sirt1 mRNA expression studies in mice: Total RNA was isolated from adipose tissue samples of 5 months old female transgenic (DBA/2 x Balb/c) mice using TRI reagent (Ambion) according to the manufacturer’s guidelines. The resulting total
RNA was subjected to DNase treatment using RNase-free DNase (Ambion). The purity of isolated RNA was measured by a NanoDrop spectrophotometer. A set concentration of RNA was reverse transcribed into cDNA and quantitative PCR was performed on ABI Prism 7500 Sequence Detection System (Applied Biosystems). Inventoried Taqman primers for Sirt1 (Mm01168521_m1) and GAPDH (Mm99999915_g1) were purchased from Applied Biosystems. Sirt1 expression was normalized to the copy number of GAPDH.

**Sirt1 protein expression studies in mice:** Adipose tissue samples were homogenized and proteins extracted using T-PER (# 78510, Pierce) along with protease inhibitors and phosphatase inhibitors (Roche, USA) from the same mice as in mRNA expression studies. After homogenization, tissue lysates were centrifuged for 30 minutes at high speed, and supernatant was collected and stored at -70°C until further analysis. Protein concentrations were measured with BCA protein assay kit (# 23225, Pierce, Rockford, USA). 20 µg/lane of protein samples containing NuPAGE LDS sample buffer (Invitrogen) and reducing agent were loaded into 4-12% NuPAGE Bis-Tris gels (Invitrogen) and were subjected to gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes (Amersham). For Sirt1 proteins, the membranes were blocked in Tris-buffered saline (TBS) with 3% milk and 0.05% Tween-20 for 1 hour at room temperature, washed with TBS-0.05% Tween-20 for 3x5 minutes and incubated overnight at +4°C with SIRT1(# 07-131, Millipore) primary antibodies (1:1000). The membranes were finally washed with TBS-0.05% Tween-20 for 3x5 minutes. For GAPDH, the membranes were blocked in Tris buffered saline (TBS) with 5% milk and 0.1% Tween-20 for 2 hours at room temperature, washed with TBS-0.1% Tween-20 for 3x5 minutes and incubated with GAPDH (# ab8245, abcam) primary antibodies (1:5000) overnight at +4°C. The membranes were washed with TBS-0.1% Tween-20 for 3x5 minutes before incubating them with secondary anti-mouse horseradish peroxidase–conjugated immunoglobulin (# NA931V, GE Health Care, UK Ltd.) (1:10000) in TBS-0.1% Tween-20 for 1 hour at room temperature. The membranes were finally washed with TBS-0.1% Tween-20 for 3x5 minutes. The bands were visualized using chemiluminescence (ECL plus, GE Health Care) and images were captured in Image Quant RT-ECL machine (Version 1.0.1, GE Health Care). Quantification of the bands was done by applying Quantity One software (Biorad). Sirt1 protein expression was normalized to GAPDH protein levels. The experiments were repeated four times.

**Statistical analysis.** Data analyses were carried out with the SPSS 14.0 for Windows. The results for continuous variables are given as mean ± SD. Variables with skewed distribution (glucose, insulin, FFAs, subcutaneous and intra-abdominal fat) were logarithmically transformed for statistical analyses. Linear regression was used to calculate the correlations. Uni- and multivariate regression model was applied to assess the determinants of the rates of the WBGU. Linear mixed model analysis was applied to adjust for confounding factors. For mixed model analysis we included the pedigree (coded as a family number) as a random factor, the tertiles as fixed factors and age as a covariate.

**RESULTS**

**Energy expenditure and insulin sensitivity**
SIRT1 expression, energy expenditure and insulin sensitivity.

Energy expenditure (EE) during the clamp positively correlated with insulin sensitivity ($r = 0.375, P = 2.8 \times 10^{-9}$; Figure 1). Even stronger correlation was found between insulin-stimulated energy expenditure $\Delta$EE (defined as EE during the clamp - EE in the fasting state) and insulin sensitivity ($r = 0.602, P = 2.5 \times 10^{-24}$). In contrast, fasting EE was not correlated with insulin sensitivity ($r = -0.004$).

To further investigate the association of EE and insulin sensitivity we analyzed the rates of WBGU/LBM during the hyperinsulinemic clamp according to the tertiles of EE (Figure 1). We did not find differences in WBGU among the tertiles of fasting EE, glucose oxidation or non-oxidative glucose disposal (data not shown). In contrast, subjects in the highest tertile of EE/LBM during the hyperinsulinemic clamp had highest WBGU/LBM (49.85 ± 15.43 vs. 55.02 ± 15.46 vs. 63.44 ± 18.76 µmol/kg of LBM/min, $P = 2.2 \times 10^{-6}$), which was attributable to both high glucose oxidative (19.54 ± 5.42 vs. 20.96 ± 5.62 vs. 22.75 ± 6.11 µmol/kg of LBM/min, $P = 0.007$) and non-oxidative glucose disposal (30.31 ± 12.81 vs. 34.06 ± 13.24 vs. 40.68 ± 16.52 µmol/kg of LBM/min, $P = 1.2 \times 10^{-5}$). These differences were even more pronounced across the tertiles of $\Delta$EE/LBM, where subjects in the highest tertile had highest WBGU/LBM (43.82 ± 13.25 vs. 55.75 ± 13.64 vs. 67.96 ± 16.31 µmol/kg of LBM/min, $P = 5.9 \times 10^{-16}$) and non-oxidative glucose disposal (26.31 ± 12.08 vs. 34.94 ± 12.24 vs. 43.38 ± 15.16 µmol/kg of LBM/min, $P = 3.6 \times 10^{-13}$).

Subjects in the highest $\Delta$EE tertile used more glucose for energy production than did subjects in the lower $\Delta$EE tertiles, as indicated by their higher respiratory quotient (RQ) in the fasting state ($P = 0.010$) and during the hyperinsulinemic clamp ($P = 1.2 \times 10^{-12}$; Figure 2). Subjects with the highest $\Delta$EE had the lowest lipid oxidation in the fasting state ($p = 1.6 \times 10^{-4}$) and during the hyperinsulinemic clamp ($P = 9.2 \times 10^{-9}$). In the fasting state, FFA levels were not different among the tertiles ($P = 0.417$), whereas during the hyperinsulinemic clamp subjects with the highest $\Delta$EE had the lowest levels of FFAs (0.05 ± 0.03 vs. 0.04 ± 0.02 vs. 0.03 ± 0.03, mmol/L, $P = 8.7 \times 10^{-7}$).

To evaluate variables associated with the rates of WBGU/LBM during the hyperinsulinemic clamp we performed univariate linear regression analysis (Table 1). High $\Delta$EE exhibited the strongest association with high WBGU/LBM, followed by low levels of low intra-abdominal adipose tissue mass and low total triglycerides. Low lipid oxidation during the hyperinsulinemic clamp and low subcutaneous adipose tissue mass were also associated with insulin sensitivity. In multivariate regression analyses a model including $\Delta$EE and intra-abdominal adipose tissue as independent variables explained a higher proportion of the variance of WBGU/LBM ($R^2 = 0.431, P = 1.7 \times 10^{-24}$) than did $\Delta$EE alone ($R^2 = 0.362$), but adding age and sex into this model did not improve substantially the $R^2$ value ($R^2 = 0.436, P = 8.0 \times 10^{-21}$). A model that included $\Delta$EE and subcutaneous adipose tissue mass as independent variables was not more strongly associated with WBGU/LBM ($R^2 = 0.379, P = 8.0 \times 10^{-21}$) than was $\Delta$EE alone.

SIRT1 mRNA expression correlation with EE, insulin sensitivity and SIRT1 target genes. To explore the determinants of insulin-stimulated EE and WBGU/LBM, we measured adipose tissue mRNA expression of SIRT1 and PGC-1α. SIRT1 mRNA expression correlated significantly with EE ($r = 0.289, P = 0.010$) and with WBGU/LBM ($r = 0.334, P = 0.002$) during the euglycemic clamp (Figure 3). No statistically significant correlation was found between SIRT1 expression and EE in the fasting state ($r = 0.142$). The correlation
SIRT1 expression, energy expenditure and insulin sensitivity

between SIRT1 expression and PGC-1α expression was 0.448 ($P = 3.5 \times 10^{-5}$). PGC-1α expression correlated significantly only with WBGU/LBM ($r = 0.387$, $P = 3.9 \times 10^{-4}$) but not with EE during the clamp ($r = 0.167$).

We also measured adipose tissue mRNA levels of several target genes of SIRT1 and PGC-1α (Table 2). SIRT1 mRNA expression correlated significantly with PGC-1β expression, estrogen-related receptor α (ERRα), nuclear respiratory factor -1 (NRF-1), mitochondrial transcription factor A (TFAM), catalase (CAT), and with several genes of the respiratory chain, including NADH dehydrogenase (ubiquinone) 1α subcomplex, 2, cytochrome c, cytochrome c oxidase subunit IV, and ATP synthase. SIRT1 mRNA expression also correlated with the expression of soluble superoxide dismutase 1. The correlations of mRNA expression of these genes with PGC-1α expression were quite similar, but somewhat weaker. Neither SIRT1 mRNA expression nor PGC-1α mRNA expression correlated with superoxide dismutase 2.

SIRT1 mRNA expression correlation in adipose tissue and skeletal muscle. In 11 subjects who had both adipose tissue and skeletal muscle biopsy the correlation of SIRT1 mRNA expression in these tissues was 0.655 ($P=0.029$). Mitochondrial DNA in skeletal muscle also correlated positively with SIRT mRNA expression in adipose tissue ($r = 0.519$) and skeletal muscle ($r = 0.533$), although the correlations were not statistically significant due to a small sample size (Supplemental table 2 which can be found in an online appendix at http://diabetes.diabetesjournals.org).

SIRT1 mRNA expression correlation with cytokines and adhesion molecules. SIRT mRNA expression negatively correlated with hs-CRP ($r = -0.241$, $P = 0.039$), but otherwise the correlations with cytokines and adhesion molecules were almost entirely non-significant (Supplementary table 1).

Sirt1 mRNA and protein correlation. Subcutaneous adipose tissue from 5 months old female mice were obtained and used for qRT-PCR and Western blot analyses. We observed a strong correlation between Sirt1 mRNA and Sirt1 protein expression levels (Figure 4, $r = 0.882$, $P < 0.001$).

DISCUSSION

Our study demonstrated that insulin-stimulated increase in EE was strongly associated with insulin sensitivity in offspring of patients with type 2 diabetes. Furthermore, we showed for the first time that adipose tissue SIRT1 mRNA expression correlated with EE and insulin sensitivity during hyperinsulinemia. Moreover, SIRT1 expression correlated with the expression of several genes regulating the mitochondrial function.

In our study high EE during hyperinsulinemia, and particularly high ΔEE were strongly associated with insulin-stimulated WBGU/LBM. These results agree with previous studies including relative small samples of lean and obese subjects (16,17). Hyperinsulinemic clamp simulates the postprandial state with high insulin levels that promote the glucose flux from circulating blood into insulin sensitive tissues. An 8-h insulin infusion in humans has been shown to increase mitochondrial mRNA transcript levels, mitochondrial protein synthesis, and ATP production (18). This response was, however, blunted in type 2 diabetic patients. In another study diabetic patients exhibited lower ATP production rate in response to high-dose insulin infusion compared to that in non-diabetic individuals (19). Thus, impaired mitochondrial fitness could be a consequence of impaired insulin action as supported by a study in mice fed a high-fat, high-sucrose diet showing that mitochondrial alterations do not
SIRT1 expression, energy expenditure and insulin sensitivity

precede the onset of insulin resistance (20). In agreement with this notion a recent study in mice demonstrated a direct effect of SIRT1 on insulin sensitivity by repressing PTP1B (21). Whether this mechanism is working also in man needs to be shown.

Alternatively, primary mitochondrial dysfunction could lead to insulin resistance. An attractive possibility to explain a causal link between impaired mitochondrial function and insulin resistance is the hypothesis that impaired OXPHOS capacity leads to intramyocellular lipid accumulation (9), and thus impaired insulin signalling and insulin resistance (22). High lipid levels in the circulating blood impair insulin-stimulated ATP production in humans (23). We observed that subjects with low insulin-stimulated EE also had higher levels of FFAs, higher lipid oxidation and lower RQ during the hyperinsulinemic clamp, reflecting changes in fuel selection in these subjects, which often lead to insulin resistance.

Further evidence supporting the hypothesis that mitochondrial activity stimulated by SIRT1 might be important for energy metabolism and insulin action are high correlations of adipose tissue SIRT1 mRNA expression with expression of genes regulating mitochondrial function. SIRT1 mRNA expression correlated significantly with PGC-1β expression which has several overlapping functions with PGC-1α in inducing genes related to OXPHOS (24). Significant correlations of SIRT1 mRNA expression were also observed with ERRα, which mediates many of the downstream effects of activated PGC-1α on mitochondrial function (25), with NRF-1, an ERRα/PGC-1α target, and with TFAM, which is a target of NRF-1 (26). Furthermore, SIRT1 mRNA levels correlated with expression of several genes regulating the respiratory chain. SIRT1 mRNA expression level also correlated with the expression of soluble superoxide dismutase 1, which protects the cell from superoxide toxicity, and with catalase, which catalyzes the decomposition of hydrogen peroxide to water and oxygen (27). Because the accumulation of reactive oxygen species can induce insulin resistance (28), the role of SIRT1 in governing SOD1 and catalase expression could cooperate with the effects of SIRT1 on the control of OXPHOS to improve insulin sensitivity. Our findings are also in agreement with recent studies in mice (4,29). Transgenic mice overexpressing SIRT1 (30) or mice having SIRT1 activity enhanced by the administration of the SIRT1 agonist, resveratrol (4,29) or a small molecule activator of SIRT1 (6), were both leaner, more hypermetabolic, and showed favorable effects on glucose and lipid metabolism. Mice treated with SRT1720, a potent synthetic activator of SIRT1, enhanced insulin sensitivity (31). Furthermore, in human studies a SIRT1 activator (SRT501) has been shown to improve glucose control (32). Adipose tissue SIRT1 mRNA expression was negatively associated with hs-CRP level which is in agreement with the anti-inflammatory effect of SIRT1 (33). The correlation of adipose tissue SIRT1 mRNA with other inflammatory markers was modest. This may reflect a poorer correlation of SIRT1 mRNA with plasma levels of cytokines compared to cytokine expression in adipose tissue.

SIRT1 mRNA expression in adipose tissue had a high correlation with skeletal muscle SIRT1 mRNA (r=0.655). Therefore, we believe that our results obtained in adipose tissue reflect metabolic changes in skeletal muscle which is the main tissue for EE and insulin sensitivity during insulin stimulation. Skeletal muscle mitochondrial DNA correlated closely with SIRT1 mRNA expression in skeletal muscle and adipose tissue giving evidence that up-regulation of the genes regulating mitochondrial biogenesis in adipose tissue and likely to reflect corresponding changes in skeletal muscle (Table 2). Finally, we demonstrated in mice
that Sirt mRNA expression and Sirt1 protein levels were highly correlated (Figure 4) demonstrating that our results are likely to be valid also at protein level. However, the limitation of our study is that we could not determine SIRT1 protein level from adipose tissue biopsies due to a small amount of tissue which we can obtain using needle biopsy techniques.

In summary, we demonstrated that insulin-stimulated EE is strongly associated with insulin-stimulated glucose uptake in offspring of subjects with type 2 diabetes. Impaired stimulation of EE by insulin is likely to reflect impaired regulation of mitochondrial function in insulin resistant states. This could be at least partially explained by low expression of SIRT1 and PGC-1α, two important master regulators of mitochondrial activity. Even though it is not possible to determine the primary defect from our cross-sectional data, disturbance in mitochondrial function and low EE were strongly associated with impaired insulin-stimulated glucose uptake. Our results give evidence that activating SIRT1 could be one of the potential mechanisms to treat insulin resistance and patients with type 2 diabetes.

ACKNOWLEDGEMENTS

Work in the Laakso laboratory was supported by the Academy of Finland and the EU FP6 (EUGENE2; LSHM-CT-2004-512013). Work in the Auwerx laboratory was supported by grants of CNRS, INSERM, ULP, EPFL, NIH (DK069966), and the EU FP6 (EUGENE2; LSHM-CT-2004-512013). Hiroyasu Yamamoto was supported by Fondation Recherche Médicale (FRM). The authors thank the members of the Laakso and Auwerx labs for discussions and technical assistance. D.A.S. is consultant to Sirtris Pharmaceuticals (a GSK company developing sirtuin-based drugs) and an inventor on Harvard patents licensed to GSK. P.E. was and C.W. is employed by Sirtris Pharmaceuticals.
REFERENCES


13. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus
SIRT1 expression, energy expenditure and insulin sensitivity


28. Houlistis N, Rosen ED, Lander ES: Reactive oxygen species have a causal role in multiple
forms of insulin resistance. Nature 2006;440:944-948

Figure legends

Figure 1. (A) Correlation between the rates of whole body glucose uptake (WBGU) and fasting energy expenditure (univariate linear regression). (B) Correlation between the rates of WBGU and energy expenditure during the hyperinsulinemic clamp and (C) Correlation between the rates of WBGU and $\Delta$ energy expenditure (defined as energy expenditure during the clamp - energy expenditure in the fasting state). (D) Rates of WBGU in the lowest (black bars), middle (stripped bars) and highest (open bars) energy expenditure tertiles according to fasting energy expenditure, (E) energy expenditure during the hyperinsulinemic clamp and (F) the $\Delta$ energy expenditure. Data are means with SD (D-F).

Figure 2. (A) Respiratory quotient in the fasting state and during the hyperinsulinemic euglycemic clamp in the tertiles of $\Delta$ energy expenditure. Data are means ± standard deviations in the lowest (black bars), middle (stripped bars) and highest tertile (open bars), (B) Lipid oxidation in the fasting state and during the hyperinsulinemic euglycemic clamp in the tertiles of $\Delta$ energy expenditure, (C) Free fatty acids in the fasting state and during the hyperinsulinemic euglycemic clamp in the tertiles of $\Delta$ energy expenditure. Data are means with SD.

Figure 3. (A) Correlation of adipose tissue SIRT1 mRNA expression level with energy expenditure during the hyperinsulinemic clamp. (B) Correlation of adipose tissue SIRT1 mRNA expression level with the rates of whole body glucose uptake in offspring of type 2 diabetic patients.

Figure 4. (A) Sirt1 protein expression western blots in subcutaneous adipose tissue from six 5 months old female mice (numbered from 1 to 6). GAPDH was used as a loading control. (B) Correlation of Sirt1 mRNA expression level with Sirt1 protein expression level ($r = 0.882, P=0.020$). A mean value of triplicates was used for Sirt1 mRNA level.
Table 1. Variables associated with the rates of whole body glucose uptake / lean body mass (univariate linear regression model, N=247).

<table>
<thead>
<tr>
<th>Independent variable</th>
<th>Standardized coefficient</th>
<th>R²</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>∆ Energy expenditure (Clamp - Fasting)</td>
<td>0.602</td>
<td>0.362</td>
<td>2.5×10^{-24}</td>
</tr>
<tr>
<td>Intra abdominal adipose tissue</td>
<td>-0.497</td>
<td>0.247</td>
<td>3.1×10^{-14}</td>
</tr>
<tr>
<td>Total triglycerides</td>
<td>-0.480</td>
<td>0.230</td>
<td>1.3×10^{-15}</td>
</tr>
<tr>
<td>Lipid oxidation / LBM during the clamp</td>
<td>-0.438</td>
<td>0.192</td>
<td>1.7×10^{-12}</td>
</tr>
<tr>
<td>Subcutaneous adipose tissue</td>
<td>-0.338</td>
<td>0.114</td>
<td>6.8×10^{-7}</td>
</tr>
<tr>
<td>Energy expenditure / LBM in the fasting state</td>
<td>-0.004</td>
<td>0.000</td>
<td>0.946</td>
</tr>
</tbody>
</table>

Table 2. Pearson correlations between adipose tissue mRNA expression of SIRT1 and PGC-1α with adipose tissue mRNA expression of genes regulating mitochondrial function (N=81)

<table>
<thead>
<tr>
<th></th>
<th>SIRT1</th>
<th>PGC1α</th>
</tr>
</thead>
<tbody>
<tr>
<td>PGC-1β</td>
<td>r = 0.358</td>
<td>r = 0.152</td>
</tr>
<tr>
<td></td>
<td>p = 0.001</td>
<td>p = 0.179</td>
</tr>
<tr>
<td>NRF1</td>
<td>r = 0.286</td>
<td>r = 0.235</td>
</tr>
<tr>
<td></td>
<td>p = 0.010</td>
<td>p = 0.036</td>
</tr>
<tr>
<td>ESRRA</td>
<td>r = 0.339</td>
<td>r = 0.260</td>
</tr>
<tr>
<td></td>
<td>p = 0.002</td>
<td>p = 0.021</td>
</tr>
<tr>
<td>TFAM</td>
<td>r = 0.379</td>
<td>r = 0.213</td>
</tr>
<tr>
<td></td>
<td>p = 0.001</td>
<td>p = 0.059</td>
</tr>
<tr>
<td>NDUFA2</td>
<td>r = 0.392</td>
<td>r = 0.273</td>
</tr>
<tr>
<td></td>
<td>p = 3.5×10^{-4}</td>
<td>p = 0.015</td>
</tr>
<tr>
<td>CYCS</td>
<td>r = 0.263</td>
<td>r = 0.159</td>
</tr>
<tr>
<td></td>
<td>p = 0.019</td>
<td>p = 0.161</td>
</tr>
<tr>
<td>COX4I1</td>
<td>r = 0.332</td>
<td>r = 0.262</td>
</tr>
<tr>
<td></td>
<td>p = 0.003</td>
<td>p = 0.020</td>
</tr>
<tr>
<td>ATP5G1</td>
<td>r = 0.248</td>
<td>r = 0.196</td>
</tr>
<tr>
<td></td>
<td>p = 0.027</td>
<td>p = 0.084</td>
</tr>
<tr>
<td>SOD1</td>
<td>r = 0.460</td>
<td>r = 0.348</td>
</tr>
<tr>
<td></td>
<td>p = 2.0×10^{-7}</td>
<td>p = 0.002</td>
</tr>
<tr>
<td>SOD2</td>
<td>r = -0.046</td>
<td>r = -0.009</td>
</tr>
<tr>
<td></td>
<td>p = 0.689</td>
<td>p = 0.940</td>
</tr>
<tr>
<td>CAT</td>
<td>r = 0.350</td>
<td>r = 0.422</td>
</tr>
<tr>
<td></td>
<td>p = 0.002</td>
<td>p = 1.3×10^{-4}</td>
</tr>
</tbody>
</table>

PGC1-β = peroxisome proliferator-activated receptor gamma, coactivator 1 beta; NRF1 = nuclear respiratory factor 1; ESRRA = estrogen related receptor alpha; TFAM = transcription factor A, mitochondrial; NDUFA2 = NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 2; CYCS = cytochrome c, somatic; COX4I1 = cytochrome c oxidase subunit IV isoform 1; ATP5G1 = ATP synthase, H+ transporting, mitochondrial F0 complex, subunit C1; SOD1 = superoxide dismutase 1, soluble; SOD2 = superoxide dismutase 2, mitochondrial; CAT = catalase. Expression of all genes were normalized to RPL0 expression.
Figure 1

**Fig. 1 A**

- Scatter plot with linear regression showing the relationship between fasting energy expenditure (cal/kg of LBM/min) and WBGU during the clamp (µmol/kg of LBM/min).
- Scatter plot with linear regression showing the relationship between energy expenditure during the clamp (cal/kg of LBM/min) and WBGU during the clamp (µmol/kg of LBM/min).
- Scatter plot with linear regression showing the relationship between ∆ energy expenditure (cal/kg of LBM/min) and WBGU during the clamp (µmol/kg of LBM/min).

**D**

- Bar chart showing fasting energy expenditure tertile with WBGU (µmol/kg of LBM/min).
- P = 0.207

**E**

- Bar chart showing energy expenditure during the clamp tertile with WBGU (µmol/kg of LBM/min).
- P = 2.2×10^-6

**F**

- Bar chart showing ∆ energy expenditure tertile with WBGU (µmol/kg of LBM/min).
- P = 2.5×10^-20
Figure 2

A

Respiratory quotient

Fasting Clamp

P = 0.010

P = 1.2 x 10^{-12}

B

Lipid oxidation (mg/l/kg of LBM/min)

Fasting Clamp

P = 1.6 x 10^{-4}

P = 9.2 x 10^{-9}

C

Free fatty acids (mmol/l)

Fasting Clamp

P = 0.417

P = 8.7 x 10^{-7}
Figure 3

A

![Graph A: Energy expenditure during the clamp (cal/kg of LBM/min)](image)

Energy expenditure during the clamp (cal/kg of LBM/min)

\[ r = 0.289 \]

\[ P = 0.010 \]

B

![Graph B: WBGU during the clamp (pmol/kg of LBM/min)](image)

WBGU during the clamp (pmol/kg of LBM/min)

\[ r = 0.334 \]

\[ P = 0.002 \]
Figure 4

A

B

SIRT1 expression, energy expenditure and insulin sensitivity